Personalized Medicine

New Targeted Therapies for Metastatic Colorectal Cancer Recommended in the Updated NCCN Guideline

Wayne Kuznar

June 2019, Vol 10, No 3 - 2019 NCCN Conference, Colorectal Cancer

Orlando, FL—A growing number of targeted therapies and immunotherapies are now recommended in the updated National Comprehensive Cancer Network (NCCN) guideline for metastatic colorectal cancer (CRC). New first-line immunotherapy options for patients with mismatch repair deficiency (dMMR) and microsatellite instability-high (MSI-H) CRC are also listed in the new guideline. [ Read More ]

FDA Expands Indication for Kadcyla to Include the Adjuvant Treatment of HER2-Positive Early Breast Cancer

Breast Cancer, FDA Approvals, News & Updates, In the News

On May 3, 2019, the US Food and Drug Administration (FDA) approved ado-trastuzumab emtansine (Kadcyla; Genentech) for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment. Patients should be selected for treatment with this agent based on an FDA-approved companion diagnostic test (Ventana Medical System’s PATHWAY anti-HER-2/neu [4B5] Rabbit Monoclonal Primary Antibody assay or INFORM HER2 Dual ISH DNA Probe Cocktail assay). [ Read More ]

Trazimera Fourth Biosimilar to Herceptin Approved for HER2-Positive Breast Cancer or HER2-Positive Metastatic Gastric or Gastroesophageal Junction Cancer

April 2019, Vol 10, No 2 - Breast Cancer, FDA Approvals, News & Updates

On March 11, 2019, the FDA approved trastuzumab-qyyp (Trazimera; Pfizer) as the fourth biosimilar to trastuzumab (Herceptin; Genentech) for the treatment of patients with HER2-positive breast cancer or HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma. This approval was based on several studies confirming that trastuzumab-qyyp is biosimilar to the originator drug, Herceptin. [ Read More ]

CAR T-Cell Therapy Associated with Unique, Acute Adverse Events Requiring Vigilant Monitoring

Wayne Kuznar

April 2019, Vol 10, No 2 - Immunotherapy

San Francisco, CA—Chimeric antigen receptor (CAR) T-cell therapy is associated with unique adverse events that require vigilant monitoring, aggressive care, and specialized management. Marco L. Davila, MD, PhD, Medical Oncologist, Blood and Marrow Transplant and Cellular Immunotherapy Program, Moffitt Cancer Center, Tampa, FL, provided an overview of this topic at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium. [ Read More ]

Genomic Markers of Response Improve Patient Selection for Immune Checkpoint Inhibitor Therapy

Wayne Kuznar

April 2019, Vol 10, No 2 - Immunotherapy

San Francisco, CA—Promising markers of response to immune checkpoint inhibition include tumor mutation burden (TMB) and genomic markers that reflect a disruption of the tumor immunity cycle, said Natalie Vokes, MD, MPhil, Medical Oncology Fellow, Dana-Farber Cancer Institute, Boston, at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium. [ Read More ]

Adjuvant Chemotherapy May Be Spared in Localized Breast Cancer If pCR Is Attained with Neoadjuvant Chemotherapy

Phoebe Starr

April 2019, Vol 10, No 2 - Breast Cancer

San Antonio, TX—Reaching pathologic complete response (pCR) after neo­adjuvant chemotherapy correlates with significantly improved event-free survival (EFS) and overall survival (OS) in patients with localized breast cancer, according to results of a large comprehensive meta-analysis presented at the 2018 San Antonio Breast Cancer Symposium. [ Read More ]

Tamoxifen 5 mg Daily as Effective as 20 mg in Early Localized Breast Cancer

Phoebe Starr

April 2019, Vol 10, No 2 - Breast Cancer

San Antonio, TX—The large, randomized TAM-01 clinical trial demonstrated that 5 mg daily of tamoxifen for 3 years halved the risk for recurrence of breast intraepithelial neoplasia—atypical ductal hyperplasia, ductal carcinoma in situ (DCIS), and lobular carcinoma in situ—in women after surgery and reduced the risk for new contralateral breast cancer by 75% compared with placebo. [ Read More ]

Updated NCCN Treatment Guideline for CML Establishes Criteria for Stopping TKI Therapy

Wayne Kuznar

April 2019, Vol 10, No 2 - 2019 NCCN Conference, Leukemia

Orlando, FL—The discontinuation of a tyrosine kinase inhibitor (TKI) is considered safe and appropriate in consenting patients with chronic-phase chronic myeloid leukemia (CML) under specific circumstances and with careful molecular monitoring, according to the updated National Comprehensive Cancer Network (NCCN) management guideline for CML. [ Read More ]